Free tools Windows power users keep installed
One-click scans. No signup required.
Mike Rousselle, Chief AI Officer at OptimizeRx, argues that AI earns its place only when it serves a concrete customer or healthcare problem, and that “decision intelligence” means a system that predicts, recommends, and learns from results, not a conversational layer placed over existing reports. In an interview published by Unite.AI on October 8, 2026, he sets out how OptimizeRx thinks about AI in life-sciences marketing, where humans should stay accountable, and how success should be measured. The interview is a primary source for what Rousselle says and how he frames the company’s work. It is not independent proof of product performance, model accuracy, privacy compliance, or clinical impact.
Who is speaking, and how much weight the interview can bear
The interview was written by Antoine Tardif, identified on the page as CEO and founder of Unite.AI, and it introduces Rousselle as OptimizeRx’s Chief AI Officer. The author bio describes nearly 15 years of AI experience and earlier roles at Athenahealth, Clarivate, and HubSpot. That biographical detail describes his career; it is not a research statistic and should not be read as evidence about OptimizeRx’s results. OptimizeRx is described as a healthcare technology company that connects life-sciences organizations with healthcare providers and patients through data, AI, and digital engagement. You can read the full interview at Unite.AI’s interview page.
As an Amazon Associate I earn from qualifying purchases.
Two company-authored OptimizeRx posts from September and October 2026 add context on positioning. They are useful for understanding what the company is trying to say, but they are not third-party verification of anything it claims.
Recommended Free Tools
Start with the customer’s problem, not the model
Rousselle’s central test for AI is blunt. In his words:
#1 Best Overall
“One of my key learnings over my career is that as “cool” as I find AI to be, and as fun as it is to utilize, it doesn’t matter AT ALL if the AI isn’t used in service of a customer’s problem.”
The practical consequence is an order of work: define the decision a marketer or clinical-commercial team needs to make, then decide whether a model, a data source, or an interface is needed to support it. Judged this way, a feature that is impressive to demonstrate but does not change a decision has little value.
Decision intelligence versus a generative layer over analytics
The interview’s most useful distinction is between two products that can look similar from the outside. Rousselle describes decision intelligence as a system that joins signals and context, predicts likely outcomes, recommends actions, and learns from what happened after those actions. A generative interface over existing analytics may make dashboards easier to query, but in his framing it does not close that loop on its own.
| Question | Generative interface over analytics (as Rousselle frames it) | Decision intelligence (as Rousselle frames it) |
|---|---|---|
| Main job | Presents or explains existing analytics through a conversational interface | Joins signals and context, predicts likely outcomes, and recommends actions |
| Feedback | Does not, by itself, use action results to change later recommendations | Records the results of actions and uses them to inform later decisions |
| Marketing example | Campaign reporting explained in plain language | Estimates which audiences are likely to respond and which channel and message may fit, then checks whether those predictions were right |
This is his explanatory model rather than reported proof that any particular deployment has produced a given lift. When evaluating a tool, the test is whether it makes an explicit prediction, recommends a specific action, and records what happened next.
How signals and audiences are built
Treatment-moment signals
Rousselle names medication switching, lab results, and upcoming appointments as signals that may indicate a useful treatment moment. He says timing and practical medical relevance matter, and that OptimizeRx guards against misleading patterns by using clinical logic, realistic treatment timelines, prescription data, and comparison groups. These are his descriptions of the company’s approach. The interview gives no independent performance study and no quantified validation of these signals.
Natural Language Audience Builder
According to Rousselle, a marketer’s prompt is interpreted into parameters such as specialties, patient volumes, and prescribing behaviors. The output is based on clinical and EHR data for healthcare-provider lists and on Micro-Neighborhood Targeting for consumer audiences. Users can inspect, rank, and refine the matched providers or consumer segments. The interview does not publish accuracy rates, technical architecture, or an independent audit of hallucination controls, so capability and safeguard statements should be attributed to Rousselle or OptimizeRx.
Patient opportunity first, then providers
In a September 24, 2026 OptimizeRx post, Rousselle wrote:
“Prescribing propensity is only part of the equation. An HCP who is theoretically persuadable isn’t particularly useful if they aren’t seeing relevant patients. That’s why a smarter HCP targeting strategy adds another dimension: Which providers are both receptive to the message and likely to see brand-eligible patients in the near future? And for that, we HAVE TO use AI.”
The post argues that provider targeting and direct-to-consumer activity can be coordinated around a shared care moment. That is the company’s point of view, and it describes intent rather than measured outcomes.
Privacy claims to read as claims
Rousselle says OptimizeRx can synchronize patient and provider marketing by looking at de-identified, aggregated patient-population trends alongside provider behavior and localized geography, rather than tracking individual patients. He says the approach respects HIPAA and state privacy requirements. The interview does not establish data flows, contractual safeguards, or legal compliance. Treat the privacy design as the company’s stated approach, and ask for documentation before relying on it for a compliance decision.
Where human accountability stays mandatory
Rousselle ties oversight to consequences. The closer an AI output comes to clinical judgment, patient eligibility, or care, the more human accountability matters. He sees governed, auditable, continuously monitored, lower-risk tasks as candidates for automation. The distinction between automating marketing operations and delegating clinical decisions is the core of his position.
| Type of task | Rousselle’s position | Examples he gives or implies |
|---|---|---|
| Lower-risk marketing operations | Candidates for automation when governed, auditable, and continuously monitored | Audience prioritization, channel selection, timing, sequencing |
| Decisions touching clinical judgment, patient eligibility, or care | Human accountability matters more as the decision moves closer to these areas | Not presented as automation candidates in the interview |
Measurement: from engagement toward outcomes
Rousselle proposes a measurement chain with three links, in this order:
Best Value
- Audience quality and timing. Did the audience reach the right providers or patients at the right moment?
- Provider behavior. Did prescribing or other HCP behavior change?
- Downstream patient effects. Where they can be measured, did patients experience an effect?
He acknowledges that the further downstream a result sits, the harder it is to measure and attribute. That creates a temptation to optimize for easy proxies such as clicks or interactions. The interview offers no measured impact figures, study design, or causal evidence, so it does not establish patient benefit.
Questions to put to any AI marketing vendor
- What exactly counts as a “signal,” and what clinical or timing logic decides whether it is relevant?
- Can you see the parameters an audience prompt was translated into before you approve a list?
- Who reviews outputs, what is logged, and can an auditor reconstruct a recommendation?
- Which data is individual, which is aggregated, and what documentation supports the privacy and legal position?
- Which outcome is the success metric, and how are comparison groups built to separate the campaign’s effect from baseline behavior?
Where Rousselle sees the field going
Rousselle expects life-sciences organizations to become more data-connected and cross-functional. He sees AI strengthening human commercial decision-making rather than making most business decisions autonomously. He is also skeptical that an “agent” framing will define the next several years; he emphasizes stronger intelligence for human teams and better organizational alignment. These are forecasts and opinions, not established outcomes.
For further listening, OptimizeRx announced on October 2, 2026 a healthcare-marketing podcast, Contra Indicated, cohosted by Rousselle and SVP of Program Management Sara Goldman. The announcement says the show brings together marketers, data scientists, physicians, and other industry voices to discuss AI, data, behavior, and healthcare-marketing assumptions. Its first season addresses reach-based marketing.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Scan for outdated or missing drivers - takes under a minute3Clear out junk files and repair common Windows errorsThe clearest attributable line in the interview is his insistence on the customer’s problem. Rousselle does not argue that AI should be trusted by default; he argues that it must be used in service of a defined decision, then measured against what happened.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
